Otto Postma is the managing director of FSHD Unlimited, and secretary of its Board. As a strategic advisor to FSHD Unlimited, he was actively involved in the establishment and early development of the Facio group of companies. He joined FSHD Unlimited from MedSciences Capital (MSC), a provider of equity funding to emerging medical companies. Prior, Otto co-founded (the predecessor of) Pharming Group NV, where he held various management positions in the fields of business and corporate development.
Frank Niemöller is Director, Finance of Facio Therapies. Frank brings over 25 years’ experience in finance and operations management in the biotech, medtech, health insurance, and internet sectors. For the last 12 years, Frank was Chief Financial Officer and Statutory Director of Optelec Holding BV, a leader in the development and supply of electronic devices for the visually impaired. Before, he was, among others, corporate controller at Pharming Group NV, the specialty pharmaceutical company developing treatments for rare diseases and unmet medical needs.
Wouter Suurmond is corporate development manager at Facio Therapies. He graduated in biomedical sciences from Utrecht University. Wouter wrote his thesis for a spinoff company from the research group of Prof Hans Clevers at the Hubrecht Institute of the Royal Netherlands Academy of Sciences. During his studies he also took minor subjects in innovation management and business and economics.
Joris De Maeyer
Joris De Maeyer is seconded to Facio from DM&S consulting (Mechelen, Belgium) as Director R&D. He has over 15 years’ experience leading outsourced and collaborative programs in drug discovery and early drug development. Joris had various roles of increasing responsibility at Johnson & Johnson, Movetis and Shire. In his most recent position as Director Discovery, he was responsible for part of Shire’s GI and CNS discovery portfolios. Joris holds a PhD (medical sciences) from Ghent University and an MSc (bioscience engineering in cell and gene biotechnology) from the Catholic University of Leuven.
Lars Bastiaanse is seconded to Facio from PMD Consulting (Riel, Netherlands) as Director Development. He has 20 years’ experience with drug development, project management, and change management. Among his clients are both established and start-up biopharmaceutical companies from Europe, the US, and Japan. Lars was general manager of Kinesis Pharma and of 3D-PharmXchange, two independent drug development consultancy firms. Prior, he held positions of increasing seniority at various Johnson & Johnson companies.